Tình trạng pháp lý: Hợp chất đang phát triển; hạn chế bằng sáng chế, chỉ dùng cho R&D/nộp hồ sơ pháp lý
Tên IUPAC: [2-[1-[1-[(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-1,2,4-triazol-4-ium-4-yl]ethoxycarbonyl-methylamino]-3-pyridinyl]methyl 2-(methylamino)acetate;hydrogen sulfate
Số EC: 619-052-6
Khối lượng phân tử: 814.8
Công thức hoá học: C₃₅H₃₆F₂N₈O₉S₂
Số CAS: 946075-13-4
Độ tinh khiết: > 99.5% (chemical purity)
Ứng dụng: Điều trị kháng nấm (aspergillosis, mucormycosis)
Dạng bào chế: Dạng đa hình vô định hình
Status: Pipeline
Therapeutic cat.: Fungal
Polymorphic form: Amorphous

Thông tin khác

Mô tả thêm:

Established in 1935 and based in the Greater Poland Voivodeship, Polpharma is a manufacturer and service provider of active pharmaceutical ingredients spanning prophylactic biological products, central nervous system drugs, cardiovascular system drugs and related APIs, offering CDMO contract manufacturing to markets across North America, Latin America, Western and Eastern Europe, Australasia, Asia, the Middle East and Africa. Drawing on 75 years of experience in the API business, Polpharma API covers the full value chain from R&D through production and supply chain management to project management, operating from a European base with R&D and two manufacturing plants, and specializes in high-potency APIs (OEB 5&6), high-potency ADC payloads, advanced linker technologies, customizable ADC development solutions, cryogenic reactions and oligonucleotides. The company is recognized for international certification, an experienced R&D team, strong reputation, high-quality service and a genuinely global market presence.